<DOC>
	<DOCNO>NCT00819247</DOCNO>
	<brief_summary>The purpose trial select dose degarelix ( FE 200486 ) . Three group patient treat six month different dos . The patient blood sample take measure Testosterone order determine efficient dose provide fast sustained castration . The patient come clinic 16 visit dependent blood sample result invite return additional blood sample two weekly basis .</brief_summary>
	<brief_title>The Efficacy Safety FE 200486 Treatment Patients Suffering From Prostate Cancer</brief_title>
	<detailed_description>Degarelix FDA regulate time trial . After completion trial degarelix approve FDA thus FDA regulate intervention .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Signed informed consent trial related activity Proven prostate cancer need endocrine treatment Testosterone level within normal range age Previous current hormonal treatment prostate cancer Candidate prostatectomy radiotherapy History severe asthma , anaphylactic reaction Quincke 's Oedema Hypersensitivity towards component FE200486 Cancer disease within last ten year except prostate cancer skin cancer Presenting significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , haematological , dermatological infectious disorder . In addition condition excessive alcohol drug abuse may interfere trial participation influence conclusion trial judge investigator Mental incapacity language barrier Having receive investigational product within last 12 week precede trial Previous participation trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>